SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 33.76 |
| Enterprise Value ($M) | 25.65 |
| Book Value ($M) | 26.60 |
| Book Value / Share | 2.47 |
| Price / Book | 1.27 |
| NCAV ($M) | 26.23 |
| NCAV / Share | 2.43 |
| Price / NCAV | 1.29 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.71 |
| Return on Assets (ROA) | -0.40 |
| Return on Equity (ROE) | -0.42 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 8.31 |
| Current Ratio | 8.31 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 29.92 |
| Assets | 30.29 |
| Liabilities | 3.70 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Bios Equity Partners, LP | 11.80 | -13.83 | |
| 13G/A | ProPhase Labs, Inc. | 5.80 | -30.64 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 6,327 | 73,623 | 8.59 | |
| 7,822 | 111,643 | 7.01 | |
| 16,884 | 106,762 | 15.81 | |
| 10,940 | 87,970 | 12.44 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| LPTX – Leap Therapeutics, Inc. | LQDA – Liquidia Corporation |
| LSTA – Lisata Therapeutics, Inc. | MBIO – Mustang Bio, Inc. |
| MBRX – Moleculin Biotech, Inc. |
Financial data and stock pages provided by
Fintel.io